Exosomes are nanometer-sized vesicles (40-100 nm diameter) of endocytic origin released from different cell types under both normal and pathological conditions. They function as cell free messengers, playing a relevant role in the cell-cell communication that is strongly related to the nature of the molecules (proteins, mRNAs, miRNAs, and lipids) that they transport. Tumor cells actively shed exosomes into their surrounding microenvironment and growing evidence indicates that these vesicles have pleiotropic functions in the regulation of tumor progression, promoting immune escape, tumor invasion, neovascularization, and metastasis. During the last few years remarkable efforts have been made to obtain an accurate definition of the protein content of tumor-derived exosomes (TDEs) by applying MS-based proteomic technologies. To date, TDEs proteomic studies have been mainly utilized to catalog TDEs proteins with the purpose of identifying disease biomarkers. The future challenge for improving our understanding and characterization of TDEs will be the implementation of new systemsdriven and proteomic integrative strategies. The aim of this article is to provide an overview of the most characterized exosomes-mediated mechanisms that contribute to the pathogenesis of cancer and to review recent proteomics data that support the protumorigenic role of TDEs.
proteins [9, 10] . Multivesicular bodies can fuse with lysosomes to degrade their content or with the plasma membrane to release the ILVs into the extracellular space. These vesicles, referred to as exosomes, display the endocytosed transmembrane proteins in the same orientation as those in the plasma membrane [11] . According to their origin, exosomes contain endocytic markers, i.e. tetraspanins and HSPs (as Hsc70 and Hsp90).
Initially, exosomes were described as vesicles released by reticulocytes, and they were thought to function as a way to remove unnecessary proteins, such as the transferrin receptor, during the maturation process into erythrocytes [12] . However, emerging evidence indicates exosomes as cell free messengers that play, within a tissue microenvironment, a relevant role in cell-cell communication [13] . Thus, today they are seen as novel mediators of intercellular signaling that act independently but synergistically with soluble growth factors [14] . How exosomes may interact with a target cell is not yet fully known and several mechanisms have been hypothesized (Fig. 1 ) [15] [16] [17] . As shown in Fig. 1A , exosomal membrane proteins can interact with the target cell in a juxtacrine fashion, acting as ligands for receptors on the cell surface. Additionally, exosomes can also fuse with the target cell resulting in the nonselective transfer of proteins and RNA from the exosome to the target cell (Fig. 1B) . Finally, in a recent paper Feng et al. showed that in phagocytic cells, exosomes can be internalized efficiently via phagocytosis [15] . Their data demonstrated that exosomes promptly adhered to the cell surface of nonphagocytic cells but were not internalized, as they could be experimentally removed by trypsinization or with extensive acid washing. In contrast, the same treatment did not remove exosomes from phagocytes [15] .
As result of each of these interaction mechanisms, exosomes are able to modulate selected cellular activities and participate in the signaling events regulating both physiological and pathological processes [2] .
In the last decade, a large number of studies have shown that tumor cells constitutively release exosomes [18] . Their detection in supernatants of cancer cells in culture as well as in plasma, sera, and other body fluids of cancer patients has been widely reported [19] [20] [21] and all available data strongly support the protumorigenic role of tumor-derived exosomes (TDEs). Currently, MS-based proteomic technologies represent one of most powerful tools for an in-depth characterization of TDEs, providing a global view of their protein content. The present review is focused on two related aspects: (i) to provide an overview of the most characterized exosome-mediated mechanisms contributing to the pathogenesis of cancer (Fig. 2) ; (ii) to review recent proteomic data that support the protumorigenic role of TDEs.
Role of TDEs in shaping the tumor microenvironment
Cancer cells begin to mold their stromal environment starting with the early phases of the neoplastic process. Today, it is known that in addition to pathways involving cell-to-cell contact and the release of soluble factors, such as TNF␣, TGF␤, VEGF, cancer cells are able to communicate with other cells of a tumor microenvironment (e.g. myeloid cells, fibroblasts) through the intercellular exchange of proteins and genetic materials via exosomes [22] . One of the first interesting clues concerning the understanding of TDEs' involvement in cancer was the presence of antigen-presenting complexes, such as MHC class I and II, and tumor antigens such as MelanA/Mart-1 and GP100, the carcinoembryogenic antigen (CEA), and the human epidermal growth factor receptor-2 (HER2) [23] [24] [25] [26] . These Figure 2 . Pleiotropic mechanisms supporting the protumorigenic role of TDEs. TDEs modulate neoplastic cell growth via autocrine stimulation and are also able to alter the premetastatic niche by promoting angiogenesis, extracellular matrix degradation, and stromal remodeling. They also create an immunosuppressive microenvironment by impairing the cytotoxic function of NK and CD8 + cells (1 and 2), by inducing the apoptosis of T cells through FAS-FASL ligation (3) and by altering the monocyte differentiation into dendritic cells and leading to the generation of myeloid suppressive cells (4) . Furthermore, TDEs interfere with the action of therapeutic agents inducing drug resistance and are implicated in transferring miRNAs and mRNAs to neighboring cells inducing gene expression modifications.
observations have led to the hypothesis that TDEs could have an immunogenic ability to induce an effective antitumor immune response, suggesting the use of exosomes as a new delivery system for tumor antigens in cancer immunotherapy [27] . However, despite these features, immunostimulatory and antitumor effects of TDEs are rarely observed in tumors. Instead, most of the experimental data support the hypothesis that TDEs play a role in preventing antitumor immune responses and promoting tumorigenesis [28, 29] . These effects are essentially due to the ability of TDEs (i) to induce a positive effect on neoplastic cell growth and survival, (ii) to contribute to the establishment of a premetastatic niche by promoting angiogenesis, extracellular matrix (ECM) degradation, and stromal remodeling, (iii) to have immunosuppressive effects, (iv) to interfere with the action of therapeutic agents by inducing drug resistance [28] [29] [30] [31] [32] . TDEs are also involved in transferring microRNAs (miRNAs) and mRNAs to neighboring cells, thereby inducing gene expression modulation [10, 33] . A schematic representation of these pleiotropic mechanisms that support the protumorigenic effects of TDEs is reported in Fig. 2. 
TDEs induce tumor cells growth and survival
Several studies have reported that TDEs play a critical role in the autocrine stimulation of cancer cells adding their effects to the protumoral action of soluble factors (Fig. 2) . One of the first evidence supporting this role showed that the intercellular transfer of the oncogenic receptor EGFRvIII, mediated by tumor exosomes to glioma cells lacking this receptor, contributed to their morphological transformation and anchorage-independent growth [34] . Furthermore, TDEs transport apoptosis inhibitory proteins, such as survivin, a member of the apoptosis inhibitor protein family [35] , they also present TGF-␤ on their surface in association with betaglycan. Exosomal delivery of TGF-␤ is capable of driving the differentiation of fibroblasts into myofibroblasts, whose enrichment in solid tumors provides an altered stroma that supports tumor growth, vascularization, and metastasis [36] .
Effects of TDEs in promoting the premetastatic niche
Metastasis formation is a complex process that depends on the ability of tumor cells to induce extensive modifications in their microenvironment including (i) the degradation and remodeling of the ECM; (ii) the formation of new blood vessels (Fig. 2) . TDEs are able to actively participate in shaping a premetastatic niche since they transport several biologically active molecules that play relevant roles in these processes. ECM metalloproteinase inducers, matrix metalloproteinases (MMPs), VEGF, and integrins have been found in exosomes [37] [38] [39] . Giusti et al. have also demonstrated that exosomes, derived from cells established from the ascitic fluid of a patient with ovarian cancer, show Cathepsin B, a cystein protease, in their membrane which has a dual effect on the ECM remodeling [40] . Other exosomal proteins that have a positive effect on the invasive behavior of cancer cells are tetraspanins, cell-surface proteins spanning four times the plasma membrane [41] . They form both homocomplexes and heterocomplexes by interacting with a large variety of transmembrane and cytosolic proteins [42] . Tetraspanins promote cell spreading, cell migration, and cable formation by regulating integrin compartmentalization, internalization, recycling, and signaling [43, 44] . In addition to enhancing the invasiveness of cancer cells, TDEs contribute to the establishment of a metastatic niche via the delivery of proteins, mRNAs and miRNAs that support angiogenesis. Tetraspanins themselves have been found to contribute to exosome-mediated angiogenesis by stimulating matrix metalloproteinase secretion and VEGF expression [45] in target cells. TDEs also contain several cytokines and growth factors, such as the tumor necrosis factors TNF-␣, IL-1␤, and TGF-␤ as well as functional receptors such as TNFR1 that enhance the recruitment of endothelial precursor cells thus promoting neoangiogenesis [46] . Hood et al. showed that melanoma-derived exosomes stimulated endothelial cells by paracrine signaling, inducing matrix remodeling and angiogenesis [47] . Chronic myelogenous leukemia (CML) cells were also shown to release exosomes that affect in vitro and in vivo angiogenesis by inducing the expression of interleukin-8 in endothelial cells. Moreover, it was reported that HUVEC cells treated with CML exosomes increased the expression of cell-cell adhesion molecules such as VCAM-1 and ICAM-1, enhancing their ability to establish cell-cell interaction with CML cells [48] .
Immunosuppressive effects of TDEs
Although the immune system can initially restrict tumor progression, its action is progressively blocked by the activation of suppressive pathways [49] involving cell-cell contact and the release of soluble factors [50] . Recently, mounting evidence has been pointing to TDEs as major participants in the immune evasion process (Fig. 2) . It was shown that melanoma-derived exosomes containing Fas ligand can cross-link Fas-positive T cells and trigger their apoptotic death [51] (Fig. 2) . Liu et al. have also reported a death-independent effect of TDEs on the immune system. They showed that the pretreatment of mice with exosomes produced by mammary tumor cells accelerated the growth of implanted tumor cells. This effect was related to ability of TDEs to block IL-2-mediated activation of natural killer (NK) cells [52] . Moreover, it was demonstrated that the TDEs containing NKG2D ligand (such as MICA*008 or ULBP3 proteins) or membrane-bound TGF␤1, triggered the downregulation of NKG2D (an activating receptor for NK, NKT, CD8(+), and gamma-delta(+) T cells) from the surface of NK cells and CD8(+) T cells. This rapid and sustained exosomemediated decrease (Fig. 2) induced a poor functional immune response and facilitated tumor immune evasion [53, 54] .
Another immune escape mechanism mediated by TDEs is the induction of myeloid suppressive cells proliferation (MDSC). These are immature myeloid cells that in cancer patients are found in large number in their lymphoid organs, blood, and tumor tissues. They spontaneously secret TGF␤ and inhibit T-cell proliferation and cytolytic functions. It was shown that melanoma-and colorectal carcinomaderived exosomes altered the monocyte differentiation into dendritic cells, leading to the generation of myeloid suppressive cells [21] (Fig. 2) . Furthermore, it was demonstrated that the MDSC-mediated promotion of tumor progression was dependent on both TGF-␤ and the lipidic mediator prostaglandin E2 (PGE2) transported by tumor exosomes [55] .
TDEs and drug resistance
TDEs may indirectly contribute to tumor progression and metastasis development by interfering with the action of therapeutic agents. It was demonstrated that cisplatin-resistant ovarian cancer cells, as well as refractory melanoma cancer cells, actively expelled anticancer drugs by enhancing the release of exosomes [31, 56] (Fig. 2) . Moreover, Safaei et al. reported that exosomes released by cisplatin-resistant cells were enriched in cisplatinum and expressed higher levels of the transporters MRP2, ATP7A, and ATP7B in comparison to sensitive cells [31] . Further studies showed that in ovarian cancer cells, resistance to cisplatinum is also associated with an increased secretion of annexin A3, a member of the Ca 2+ and phospholipid-binding annexin family, that prevents the uptake or accumulation of platinum in cells [57] . Electron microscopy observations have shown that annexin A3 detected in culture medium was localized in exosomes, revealing yet another exosome-mediated mechanism that affects a drug's action [58] .
Recently, Battke et al. have shown that exosomes can hamper the action of anticancer therapies by interfering with antibody-based drugs. The authors demonstrated that breast cancer cell lines overexpressing HER2, release exosomes expressing a full-length HER2 molecule that is able to bind, both in vitro and in vivo, to the HER2 antibody Trastuzumab resulting in a reduced amount of antibodies available for the antibody-dependent cytotoxicity ( Fig. 2) [32].
TDEs-mediated horizontal transfer of RNAs
Recent findings have shown that exosomes contain both mRNA, and miRNAs molecules that can be delivered to recipient cells where they properly function [59] (Fig. 2) . Valadi et al. demonstrated that after the transfer of mouse exosomal RNAs to human mast cells, new mouse proteins were found in the target cells, indicating that transferred exosomal mRNAs can be translated. Similarly, it has been demonstrated that exosomes also transfer miRNAs into target cells, thus regulating gene expression by their canonical binding to the target messengers [10, 33] . The horizontal transfer of RNAs mediated by TDEs has several consequences in the regulation of tumor progression and metastasis [33, 60, 61] . A specific role in cancer-to-endothelial cell communication was recently reported by Umezu et al. They showed that miR-17-92 cluster, especially miR-92a, contained in leukemia cells (K562) exosomes can be transferred to HUVEC endothelial cells where it significantly reduces the expression of integrin ␣5 (a target gene for miR-92a). Data obtained in this study demonstrated that K562 exosomes did not affect the growth of HUVECs, but selectively increased endothelial cell migration and tube formation [61] .
In a recent work, Fabbri et al. have showed that miR-21 and -29a, secreted by lung cancer cells via exosomes, can also function by acting as ligands to the human Toll-like receptor 8 (TLR8) in immune cells and by triggering a TLRmediated prometastatic inflammatory response. Thus, by acting as paracrine agonists of TLRs, these secreted miRNAs are able to regulate tumor growth and spread, working as key regulators of the tumor microenvironment [60] .
Contribution of proteomics study in defining the protumoral role of TDEs
In the last years the increased application of proteomic technologies has significantly contributed to deeply delineate the protein profile of exosomes from a variety of cultured cells and body fluids (such as plasma, urine, and tumor effusions) [62] [63] [64] [65] [66] . A part of these studies are specifically focused on TDEs and the data are providing new insights for understanding their role in the regulation of tumor microenvironment [62] [63] [64] [65] .
Technical features of TDE proteomics
In the field of exosome proteomics, the purification and characterization of nanovesicles are the two most critical points to control in order to avoid false-positive identifications due to the presence of contaminating components [67] . Factors such as biological matrices (e.g. cell culture media or biological fluids) must be carefully considered in the choice of suitable methods for exosome purification allowing the elimination of the abundant nonexosomal proteins including Igs and albumin. The most used isolation strategies involve a combination of different methods such as: differential centrifugation, filtration, concentration, flotation density gradient, and immunocapture beads. Moreover, after a first isolation step, an appropriate characterization by transmission electron microscopy, fluorescent activated cell-sorted analysis, and/or western blot is suggested to validate the relevance of the recovered material [2, 67] . However, despite the efforts to improve the purification of exosomes, the methods that are typically used today are still not completely able to guarantee the absence of nonexosomal contaminant proteins and for this reason the strategies used to purify exosomes often differ between laboratories with little consensus concerning their criteria of purity. Nevertheless, during the last few years the advances in proteomic technology have facilitated the collection of extensive exosome protein data sets. Among the about 80 papers on exosome proteomics (including reviews) published during the last 80 years, less than 20 are on TDEs. Moreover, most of them describe expression proteomic studies focused on defining exosome proteome profiling and very often are specifically orientated toward the discovery of tumor biomarkers [25, 62, 63, 65, 68] .
Currently, two strategies are mostly used to define an exosome protein content: the first analytical approach is based on gel electrophoresis separation followed by MS analysis; the second one is based on the application of several shotgun proteomics procedures such as LC-MS/MS or multidimensional protein identification technology (MudPIT) [69] (Fig. 3) .
In the former approach, proteins are first separated by SDS-PAGE (1D or 2DE) and gel bands or spots are then cut, trypsin-digested, and analyzed by MS. Peptide mixtures derived from 2D gel spots that can be analyzed by PMF, performing MALDI-TOF MS or by peptide sequencing, performing an MS/MS [69, 70] . For the identification of proteins separated by 1D gel, since a single gel band may contain more than one protein, the classical approach based on PMF cannot be used. Therefore, tryptic peptides must be separated by nanoLC systems online connected through an ESI source with different types of mass spectrometers [16, 71] or analyzed off-line by MALDI-TOF/TOF [65] .
Alternatively, for the proteomic profiling of exosomes, gelfree methods such as LC-MS/MS or MudPIT have been used. The LC-MS/MS method allows for the concentration and isolation of hundreds of selected peptides from extremely complex mixtures obtained through the proteolytic digestion of proteins, before sequencing by MS [63, 72] . In MudPIT analysis, peptides derived from digested proteins are first separated with a strong cation exchange column followed by a RP separation online connected to LTQ or Orbitrap mass spectrometer, thus combining the separation steps with the identification process [73] .
Proteomics data set of TDEs
In general, the available published data on TDE proteomics clearly shows that proteins identified in these nanovesicles (both released by tumor cell lines and isolated from body fluids) can be sorted into two groups: one group represents a conserved set of proteins irrespective of exosome origin; the second one is formed by proteins specifically related to the producer host cell, showing that TDEs have a unique cell-specific protein composition.
Within the group of common proteins, those most frequently identified belong to the following classes: membrane adhesion proteins (integrins); components of the ESCRT machinery (alix, TSG101, vacuolar protein sorting-associated protein 28 homolog (vps-28), vacuolar protein sorting-associated protein 4B (vps-4B), ubiquitinlike modifier-activating enzyme, and ubiquitin); membrane transport/trafficking (annexins, Rab protein family); cytoskeletal components (actin, cytokeratins, ezrin, tubulin, and myosin); lysosomal markers (lysosome membrane protein 2, cathepsin-D, CD63, LAMP-1/2); antigen presentation proteins (HLA class I and II/peptide complexes); metabolic enzymes (GAPDH, pyruvate, enolase alpha); HSPs (Hsc70, Hsp70, Hsp90); kinases (LYN, MINK1, and MAP4K4); tetraspanins (CD9, CD81, CD82, tetraspanin-8) proteases (ADAM10, DPEP1, ST14); transporters (ATP7A, ATP7B, MRP2, SLC1A4, SLC16A1, CLIC1); receptors (CD46, CD55, NOTCH1) [16, 26, 65, 70, 74] . Many of these proteins have been cataloged in the ExoCarta website (http://www.exocarta.org/).
As more proteome studies are performed, it is becoming ever more apparent that beyond the set of conserved proteins, TDEs contain proteins that are not found in the exosomes from both nontumor cells and/or body fluids of healthy individuals [16, 25, 26, 62, 63, 65, 74, 75] . All of the proteomics data that have been obtained so far demonstrates that TDEs express a discrete set of proteins specifically related to the tumor phenotype and involved in cell proliferation, antigen presentation, signal transduction, migration, invasion, and angiogenesis, supporting the hypothesis that exosomes may play a crucial role in modulating tumor progression and preparing the metastatic niche.
A large amount of proteomic data regarding TDEs has been obtained from studies on human colorectal cancer (CRC) cell-derived exosomes. In the first global proteomic analysis performed on exosomes released from HT29 CRC cells, a total of 547 proteins were identified and among them 181 had never been previously described as exosome proteins. Most of these proteins were involved in exosome biogenesis, but a part of them were related to processes related to tumorigenesis [75] . In particular, this subset of 28 proteins have a role in cancer development, including the ADAM10, 14-3-3 proteins, CD44, CD82, CD9, Alix (PDC6I), Ras-related proteins, syntenin-1, MIF, and tetraspanin 8, which were already described in other cell-derived exosomes, as well as the newly reported proteins in exosomes such as ␤-catenin, RACK1, chondroitin sulfate proteoglycan NG2, E-cadherin, and ephrin B1. All of them contribute to the tumor phenotype and are differentially involved in the regulation of tumor progression via the promotion of tumor growth, migration, invasion, immune modulation, metastasis, and angiogenesis [75] (Table 1) .
More recently, a comparative proteomic analysis of LIM1215 (colorectal cancer)-derived exosomes with human urine-and murine mast cell-derived exosomes showed that among the 394 identified proteins, 250 were exclusively present in the LIM1215 exosomes, revealing a tissueassociated protein signature. Among them, a subset of proteins known to be expressed in colorectal cancer tissues was also found. This set included A33 antigen, cadherin-17, CEA, epithelial cell surface antigen (EpCAM), proliferating cell nuclear antigen, epidermal growth factor receptor, mucin 13, misshapen-like kinase 1, mitogen-activated protein kinase 4, claudins (1, 3, and 7), centrosomal protein 55 kDa, ephrin-B1 and -B2, and the enzyme phospholipid scramblase [16] ( Table 1) . Interestingly, this study also revealed that the LIM1215 exosome proteins could be categorized in some of the seven cancer hallmark features [76, 77] . In particular, 36% belong to the category of self-sufficiency in growth signals, 24% had a role in limitless replicative potential, 17% of the proteins were upregulated in colon cancer metastasis, whereas 6% function in apoptosis evasion [16] .
Similar results were reported by Tauro and colleagues in a study focused on the proteomic characterization of exosomes derived from another colon carcinoma cell line (LIM1863). They found that among the 171 unique proteins identified in these exosomes, many were associated with cancer cell proliferation, invasion, and metastasis such as c-Met protein (hepatocyte growth factor receptor), amphiregulin (AREG), various ephrins (EFNB1, EFNB2), and Eph receptors (EPHA2-8, EPHB1-4), components involved in Wnt (␤-Catenin and TNIK) and Ras (CRK and GRB2) signaling, and several key components associated with colorectal cancer, including CEACAM1 and 5, FAT1, and CDH17 [74] . It is a well-known fact that CEACAM5 (CEA) is found to be overexpressed in over 90% of human gastrointestinal and pancreatic cancers and, in particular it is associated with metastatic potential in colon cancer [78, 79] (Table 1) .
Additional information relative to the protein composition of CRC exosomes was provided from the proteome profiling of highly purified exosomes derived from human CRC ascites [63] . In this study, together with proteins related to tumor progression and already identified in previous studies [16, 75] , the authors reported the presence of new proteases such as aminopeptidase N, angiotensin-converting enzyme, which play important roles in tumor invasion, metastasis, and angiogenesis as well as several proteins that affect epithelial cellular integrity and polarity (as galectins, Crumbs homolog 2, adherens junction and tight-junction proteins, and claudins) [63] (Table 1) .
Other interesting data supporting the role of TDEs in tumor biology was produced by proteomics studies carried out on other types of human tumors, such as breast cancer [70] , bladder cancer [65] , mesothelioma [25] , melanoma [26] , and medulloblastoma [80] , but also from murine insulinoma [71] . For example, the statistically based, unbiased overrepresentation analysis of human bladder cancer exosomes highlighted that these exosomes expressed proteins strongly related to neoplastic diseases in general and to carcinomas in particular.
Moreover, it was demonstrated that in the biological processes category, a large proportion of identified proteins had functional roles in the control of the cytoskeleton, intercellular adhesion, matrix adhesion processes, and protein foldingrelated processes [65] . All of these data clearly demonstrates that TDEs are characterized by a proteome profile strongly related to their origin and determining their functions. Table 1 shows a summary of proteins identified in TDEs known for their role in regulating several steps of cancer progression. 
The new challenge of TDE proteomics
Most of the proteomic studies performed on TDEs up to now have allowed for the catalogization of the proteins that they contain. However, although TDEs' proteins have been also classified for their biological functions, from a Systems Biology perspective the large-scale nature of TDE proteomics data has been so far largely untapped. Proteomics experimental results, beyond a rapid identification of a high number of proteins in a single analysis, provide distinct data types that can be used to quantify proteins between different proteome states, including the temporal variation of the proteome, to determine the complete primary structure of proteins including PTMs, and to determine protein interactions [81] . These aspects of expression and functional proteomics could provide new knowledge for understanding the mechanisms of protein sorting into TDEs, the biological meaning of some proteins in TDEs, and the interrelationships between TDE proteins.
Few papers, all published during the last 3 years, have reported data concerning quantitative and PTMs analysis of TDE proteins, as well as data depicting protein-protein interaction networks in TDEs.
In a work performed on breast cancer exosomes, a quantitative and comparative proteomic analysis was carried out between exosomes and whole cell lysate. This analysis revealed that vesicles had a distinctive protein profile in comparison to the producing cell. The functional clustering of the enriched exosomal proteins showed that most of them belonged to functional classes of cytoskeleton, the regulation of programmed cell death and signal proteins that, as is published, are differentially involved in mechanisms affecting the malignant progression of cancer [70] . Other significant data were obtained by a quantitative proteomics study carried out on the A431 human epidermoid carcinoma. In this work, the authors reported that when under hypoxia, cells secreted higher levels of proteins involved in angiogenesis, focal adhesion formation, ECM-receptor interaction, and immune cell recruitment in comparison to cells undergoing normoxic and reoxygenation conditions. They found that more than 50% of these secreted proteins, predominantly classified as cytoplasmic and membrane proteins, were localized in exosomes [82] . Currently, new methods of performing quantitative proteome analyses based on differential labeling protocols or labelfree techniques as well as a vast number of software tools for the analysis of quantitative proteomics data are almost monthly described in the literature [69, [83] [84] [85] . During the next few years, the application of these accurate quantitative techniques could represent one of most challenging issues in the field of TDE proteomics.
Although it is well known that the identification of PTMs is very often essential for understanding the real function of proteins and their localization within cells or cell organelles, only one paper in the published literature reports data concerning PTMs of exosomal proteins. In this work, Lee and co-workers analyzed exosomes derived from murine insulinoma cells and showed that some proteins (such as ubiquitin and HSP90␤) were present in secreted vesicles as multiple populations, distinct from those observed in cell lysate. By analyzing data obtained combining techniques such as 1D gel separation, western blot, and nanoLC-ESI-q-TOF MS/MS, the authors highlighted that these multiple forms of a same protein were due to several PMTs, including ubiquitination and phosphorylations. On the basis of these observations, they propose that some uniquely modified proteins could be located in exosomes. However, the relationship between PTMs detected in exosomes and their biogenesis or their functions was not further investigated and no more data are currently available.
Doubtless, different independent difficulties (such as low abundance, lability of the modifications) have made it challenging to perform a PTM global analysis so far. However, technological advances in MS-based proteomics have allowed some critical points to be overcome and MS-based PTM analysis is now quite successful. Good results have been produced not only for phosphorylation (the more studied PTM), but also for lysine acetylation or methylation, N-glycosylation, ubiquitination, sumoylation, and others that have also been investigated in a quantitative manner [81] and references therein]. The possibility to characterize the PTMs in TDEs proteins as well as their functional effects, may represent an outstanding development of TDEs proteomic studies, furthering our understanding of TDE roles in tumor microenvironment.
Finally, today the characterization of protein networks is a highly valued goal of the postgenomic studies. However, this aspect remains almost completely unexplored in the field of exosome proteomics. The only data available in literature comes from two recent studies in which exosomes derived from human medulloblastoma and colorectal carcinoma cells were analyzed. Proteomic data obtained in these studies allowed the construction and analysis of proteinprotein interaction networks for TDEs for the first time, revealing that exosomal proteins are closely interconnected via physical interactions and cluster into functional modules involved in the biogenesis of exosomes and in several processes regulating tumor progression (as cell proliferation, cell migration, and immune suppression) [80, 86] . Interestingly, what has clearly emerged from the work on CRCderived exosomes is that these TDEs have several hub proteins, with many other vesicular proteins that have few interacting partners, and well-connected clusters similar to those identified in other subcellular networks. However, there is a significant amount of evidence that indicates that groups of proteins with roles in specific biological processes and molecular functions are highly enriched or depleted in TDEs, suggesting that TDEs are extracellular organelles distinct from other intracellular organelles and compartments [86] . Further Systems Biology approaches could provide a new integrated view of TDEs, and the resulting interactome data, analyzed extensively through bioinformatic methods, would offer new tools for defining the organization and function of exosomes.
In conclusion, the involvement of TDEs in promoting tumor progression is supported by all of the proteomic data obtained from several types of tumors. However, up until now the exosome proteomic study has been often utilized to catalog TDEs' proteins in order to find disease biomarkers rather than to predict the functional activities of the vesicles. Thus, new efforts must currently focus on the development of new perspectives to perform adequate quantitative, PTMs, and protein interaction analyses with the aim of creating predictive models of TDEs in the field of Systems Biology.
